MICROENCAPSULATED TRANSDERMAL PENETRATION ENHANCERS

微囊透皮渗透促进剂

• 批准号: 3498353
• 负责人: KELLY L SMITH
• 金额: $ 4.93万
• 依托单位: BEND RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 1989
• 资助国家: 美国
• 起止时间: 1989-03-01 至 1989-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3498353
• 关键词: dosage forms; drug delivery systems; high performance liquid chromatography; pharmacokinetics; skin; skin absorption; swine; topical drug application; unsaturated fatty acids

The transdermal route to drug delivery has the advantages associated with rate-controlled drug-delivery systems (e.g., greater safety, effectiveness, and convenience). In addition, unlike other rate-controlled systems, transdermal drug delivery avoids hepatic "first pass" effects and gastrointestinal incompatibility, and offers the potential for localized drug delivery. The primary factor responsible for the limited use of transdermal drug delivery is the low transdermal permeability of most drugs. Although a number of agents have been identified that increase the transdermal permeation of specific drugs, the utility of such agents, termed penetration enhancers, is often limited by rapid clearance from the application site through evaporation or transdermal permeation. In the proposed program, we will determine whether the utility of penetration enhancers can be increased by sustaining their delivery to the skin surface. Our principal objective will be to demonstrate that microencapsulated enhancers have the ability to maintain effective enhancement properties over extended periods of time. By sustaining the delivery of enhancers, we expect to increase the amount of drug that can be delivered in a single topical application and to extend the delivery lifetimes of current transdermal delivery systems.

透皮途径通往药物的途径具有优势 与费率控制的药物交付系统有关（例如， 更大的安全性，有效性和便利性）。 此外， 与其他费率控制的系统不同，透皮药物输送 避免肝“第一次过去”效果和胃肠道 不兼容，并为局部药物提供了潜力 送货。 负责透皮使用有限使用的主要因素 药物输送是大多数药物的透皮渗透性低。 尽管已经确定了许多代理商 特定药物的透皮渗透，这种效用 代理，称为渗透增强剂，通常受到快速的限制 通过蒸发或 透皮渗透。 在拟议的计划中，我们将确定 可以通过维持其交付来增加渗透增强剂 到皮肤表面。 我们的主要目标是 证明微封装的增强器具有 在长期内保持有效的增强特性 时间。 通过维持增强剂的交付，我们希望 增加可以在单一中输送的药物量 局部应用并延长当前的递送寿命 透皮输送系统。